Enzymatic glycan remodeling–metal free click (GlycoConnect™) provides homogenous antibody-drug conjugates with improved stability and therapeutic index without sequence engineering

References

• Lambert JM, van Delft FL. Introduction to antibody-drug conjugates. In: van Delft FL, Lambert JM, editors. Chemical linkers inantibody-drugconjugates, Royal Society of Chemistry; 2021, chapter 1. p. 1–10. doi:10.1039/9781839165153.
   Google Scholar
• Thurston DE, Jackson PJM, editors. Cytotoxic payloads for antibody–drug conjugates.. Royal Society of Chemistry; 2019. doi:10.1039/9781788012898.
   Google Scholar
• Walsh SJ, Bargh JD, Dannheim FM, Hanby AR, Seki H, Counsell AJ, Ou X, Fowler E, Ashman N, Takada Y, et al. Site-selective modification strategies in antibody-drug conjugates. Chem Soc Rev. 2021;50(2):1305–53. doi:10.1039/d0cs00310g.
   PubMed Web of Science ®Google Scholar
• Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008;26:925–32. doi:10.1038/nbt.1480.
   PubMed Web of Science ®Google Scholar
• van Berkel SS, van Delft FL. Enzymatic strategies for (near) clinical development of antibody-drug conjugates. Drug Discov Today. 2018:30. doi:10.1016/j.ddtec.2018.09.005.
   Google Scholar
• Chin JW, Cropp T, Anderson JC, Mukherji M, Zhang Z, Schultz PG. An expanded eukaryotic genetic code. Science. 2003;301:964–67. doi:10.1126/science.1084772.
   PubMed Web of Science ®Google Scholar
• van Geel R, Wijdeven MA, Heesbeen R, Verkade JMM, Wasiel AA, van Berkel SS, van Delft FL. Chemoenzymatic conjugation of toxic payloads to the globally conserved N‐glycan of native mAbs provides homogeneous and highly efficacious antibody−drug conjugates. Bioconj Chem. 2015;26:2233–42. doi:10.1021/acs.bioconjchem.5b00224.
   PubMed Web of Science ®Google Scholar
• Verkade JMM, Wijdeven MA, van GR, Janssen BMG, van BSS, van DFL. A polar sulfamide spacer significantly enhances the manufacturability, stability, and therapeutic index of antibody–drug conjugates. Antibodies. 2018;7(1):12. doi:10.3390/antib7010012.
   Google Scholar
• See https://synaffix.com/partnered-pipeline/, accessed Jan. 9th 2022.
   Google Scholar
• Beacon targeted therapies ADC database. [ accessed2022Jan.9]. https://www.beacon-intelligence.com.
   Google Scholar
• Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology. 2015;25:1325–34. doi:10.1093/glycob/cwv065.
   PubMed Web of Science ®Google Scholar
• Freeze HH, Kranz C. Endoglycosidase and glycoamidase release of N-linked glycans. Curr Protoc Mol Biol. 2010;89:17.13A.1. doi:10.1002/0471142735.im0815s83.
   Google Scholar
• Collin M, Olsén A. EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG. EMBO J. 2000;20:3046–55. doi:10.1093/emboj/20.12.3046.
   Web of Science ®Google Scholar
• Sjögren J, Struwe WB, Cosgrave EFJ, Rudd PM, Stervander M, Allhorn M, Holland SA, Nizet V, Collin M. EndoS2 is a unique and conserved enzyme of serotype M49 group A streptococcus that hydrolyses N-linked glycans on IgG and α1-acid glycoprotein. Biochem J. 2013;455:107–18. doi:10.1042/BJ20130126.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Shankara S, Roy A, Qiu H, Estes S, McVie-Wylie A, Culm-Merdek K, Park A, Pan C, Edmunds T. Development of a simple and rapid method for producing non‐fucosylated oligomannose containing antibodies with increased effector function. Biotechn Bioengin. 2008;99:652–65. doi:10.1002/bit.21598.
   PubMed Web of Science ®Google Scholar
• Clark PM, Dweck JF, Mason DE, Hart CR, Buck SB, Peters EC, Agnew BJ, Hsieh-Wilson LC. Direct in-gel fluorescence detection and cellular imaging of o-glcnac-modified proteins. J Am Chem Soc. 2008;130:11576–77. doi:10.1021/ja8030467.
   PubMed Web of Science ®Google Scholar
• Zeglis BM, Davis CB, Aggeler R, Kang HC, Chen A, Agnew B, Lewis JS. Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry. Bioconj Chem. 2013;24:1057–67. doi:10.1021/bc400122c.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan B, Qasba PK. Structure-based design of β−1,4-galactosyltransferase I (β 4Gal-T1) with equally efficient N-Acetylgalactosaminyltransferase activity. J Biol Chem. 2002;277:20833–39. doi:10.1074/jbc.M111183200.
   PubMed Web of Science ®Google Scholar
• Kawar ZS, Van Die I, Cummings RD. Molecular cloning and enzymatic characterization of a UDP-GalNAc: glcNAcβ-R β1,4-N-acetylgalactosaminyltransferase from caenorhabditis elegans. J Biol Chem. 2002;277:34924–32. doi:10.1074/jbc.M206112200.
   PubMed Web of Science ®Google Scholar
• Laughlin ST, Bertozzi CR. In vivo imaging of Caenorhabditis elegans glycans. ACS Chem Biol. 2009;4:1068–72. doi:10.1021/cb900254y.
   PubMed Web of Science ®Google Scholar
• Burnham-Marusich AR, Snodgrass CJ, Johnson AM, Kiyoshi CM, Buzby SE, Gruner MR, Berninsone PM. Metabolic labeling of Caenorhabditis elegans primary embryonic cells with azido-sugars as a tool for glycoprotein discovery. Plos One. 2012;7:e49020. doi:10.1371/journal.pone.0049020.
   PubMed Web of Science ®Google Scholar
• Hoskins RA, Carlson JW, Kennedy C, Acevedo D, Evans-Holm M, Frise E, Wan KH, Park S, Mendez-Lago M, Rossi F, et al. Sequence finishing and mapping of Drosophila melanogaster heterochromatin. Science. 2007;316:1625–28. doi:10.1126/science.1139816.
   PubMed Web of Science ®Google Scholar
• Vadaie N, Jarvis DL. Molecular cloning and functional characterization of a Lepidopteran insect β4-N-acetylgalactosaminyltransferase with broad substrate specificity, a functional role in glycoprotein biosynthesis, and a potential functional role in glycolipid biosynthesis. J Biol Chem. 2004;279:33501–18. doi:10.1074/jbc.M404925200.
   PubMed Web of Science ®Google Scholar
• Bülter T, Schumacher T, Namdjou DJ, Gutiérrez Gallego R, Clausen H, Elling L. Chemoenzymatic synthesis of biotinylated nucleotide sugars as substrates for glycosyltransferases. ChemBioChem. 2001;2:884–94. doi:10.1002/1439-7633(20011203)2:12<884::AID-CBIC884>3.0.CO;2-2.
   PubMed Web of Science ®Google Scholar
• Bosco M, Le Gall S, Rihouey C, S C-B, Bardor M, Lerouge P, Pannecoucke X. 6-azido-d-galactose transfer to N-acetyl-D--glucosamine derivative using commercially available β-1,4-galactosyltransferase. Tetrahedron Lett. 2008;49:2294–97. doi:10.1016/j.tetlet.2008.02.018.
   Web of Science ®Google Scholar
• Dommerholt J, Schmidt S, Temming R, Hendriks LJA, Rutjes FPJT, van HJCM, Lefeber DJ, Friedl P, van DFL. Readily accessible bicyclononynes for bioorthogonal labeling and three‐dimensional imaging of living cells. Angew Chem Int Ed. 2010;49:9422–25. doi:10.1002/anie.201003761.
   PubMed Web of Science ®Google Scholar
• Fujii T, Reiling C, Quinn C, Kliman M, Mendelsohn BA, Matsuda Y. Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates. Explor Target Antitumor Ther. 2021;2:576–85.
   PubMedGoogle Scholar
• Benjamin SR, Jackson CP, Fang S, Carlson DP, Guo Z, Tumey LN. Thiolation of Q295: site-specific conjugation of hydrophobic payloads without the need for genetic engineering. Mol Pharmaceut. 2019;16:2795–807. doi:10.1021/acs.molpharmaceut.9b00323.
   PubMed Web of Science ®Google Scholar
• Nishimura SI, Hato M, Hyugaji S, Feng F, Amano M. Glycomics for drug discovery: metabolic perturbation in androgen‐independent prostate cancer cells induced by unnatural hexosamine mimics. Angew Chem Int Ed. 2012;51:3386–90. doi:10.1002/anie.201108742.
   PubMed Web of Science ®Google Scholar
• Hang HC, Yu C, Kato DL, Bertozzi CR. A metabolic labeling approach toward proteomic analysis of mucin-type O-linked glycosylation. Proc Nat Acad Sci. 2003;100:14846–51. doi:10.1073/pnas.2335201100.
   PubMed Web of Science ®Google Scholar
• Sarabia F, Martín-Ortiz L, López-Herrera FJ. Synthetic studies towards the tunicamycins and analogues based on diazo chemistry. total synthesis of tunicaminyl uracil. Org Biomol Chem. 2003;1:3716–25. doi:10.1039/B307674A.
   PubMed Web of Science ®Google Scholar
• Cai L, Guan W, Wang W, Zhao W, Kitaoka M, Shen J, O’Neil C, Wang PG. Substrate specificity of N-acetylhexosamine kinase towards N-acetylgalactosamine derivatives. Bioorg Med Chem Lett. 2009;19:5433–35. doi:10.1016/j.bmcl.2009.07.104.
   PubMed Web of Science ®Google Scholar
• Mamidyala SK, Dutta S, Chrunyk BA, Préville C, Wang H, Withka JM, McColl A, Subashi TA, Hawrylik SJ, Griffor MC, et al. Glycomimetic ligands for the human asialoglycoprotein receptor. J Am Chem Soc. 2012;134:1978–81. doi:10.1021/ja2104679.
   PubMed Web of Science ®Google Scholar
• Megia-Fernandez A, Morales-Sanfrutos J, Hernandez-Mateo F, Santoyo-Gonzalez F. Synthetic applications of cyclic sulfites, sulfates and sulfamidates in carbohydrate chemistry. Curr Org Chem. 2011;15:401–32. doi:10.2174/138527211794072542.
   Web of Science ®Google Scholar
• Hu X, Lerch TF, Xu A. Efficient and selective bioconjugation using surfactants. Bioconj Chem. 2018;29:3667–76. doi:10.1021/acs.bioconjchem.8b00594.
   PubMed Web of Science ®Google Scholar
• Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, Oflazoglu E, Toki BE, Sanderson RJ, Zabinski RF, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconj Chem. 2006;17:114–24. doi:10.1021/bc0502917.
   PubMed Web of Science ®Google Scholar
• Poon KA, Flagella A, Beyer J, Tibbitts J, Kaur S, Saada O, Yi JH, Girish S, Dybdal N, Reynolds T. Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. Toxicol Appl Pharmacol. 2013;273:298–313. doi:10.1016/j.taap.2013.09.003.
   PubMed Web of Science ®Google Scholar